Amedisys Company Profile (NASDAQ:AMED)

About Amedisys (NASDAQ:AMED)

Amedisys logoAmedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness. The Personal care segment provides patients with assistance with the essential activities of daily living.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Home Healthcare Services
  • Sub-Industry: Health Care Services
  • Symbol: NASDAQ:AMED
  • CUSIP: 02343610
  • Web:
  • Market Cap: $1.98154 billion
  • Outstanding Shares: 33,728,000
Average Prices:
  • 50 Day Moving Avg: $61.69
  • 200 Day Moving Avg: $53.66
  • 52 Week Range: $34.58 - $65.91
  • Trailing P/E Ratio: 43.96
  • Foreward P/E Ratio: 24.73
  • P/E Growth: 1.51
Sales & Book Value:
  • Annual Revenue: $1.44 billion
  • Price / Sales: 1.39
  • Book Value: $14.31 per share
  • Price / Book: 4.15
  • EBIDTA: $95.5 million
  • Net Margins: 3.16%
  • Return on Equity: 12.60%
  • Return on Assets: 7.84%
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 1.32%
  • Quick Ratio: 1.32%
  • Average Volume: 257,865 shs.
  • Beta: 0.94
  • Short Ratio: 12.82

Frequently Asked Questions for Amedisys (NASDAQ:AMED)

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) announced its earnings results on Tuesday, May, 2nd. The company reported $0.47 earnings per share for the quarter, topping analysts' consensus estimates of $0.41 by $0.06. The business earned $370.46 million during the quarter, compared to the consensus estimate of $370.03 million. Amedisys had a net margin of 3.16% and a return on equity of 12.60%. During the same quarter last year, the firm earned $0.33 earnings per share. View Amedisys' Earnings History.

When will Amedisys make its next earnings announcement?

Amedisys is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Amedisys.

Where is Amedisys' stock going? Where will Amedisys' stock price be in 2017?

8 equities research analysts have issued twelve-month target prices for Amedisys' stock. Their forecasts range from $54.00 to $65.00. On average, they anticipate Amedisys' share price to reach $58.29 in the next twelve months. View Analyst Ratings for Amedisys.

What are analysts saying about Amedisys stock?

Here are some recent quotes from research analysts about Amedisys stock:

  • 1. According to Zacks Investment Research, "Over the last month, Amedisys has steadily traded above the Zacks categorized Medical-Outpnt/Hm Care industry. Market is particularly positive on the company’s consistent and stellar Home Health division’s performance with solid organic growth in Medicare and non-Medicare revenues. We are also upbeat about the company’s initiative for strategically fit merger and acquisition activities, the most recent deal being East Tennessee Personal Care Service. The company’s strong cash position further bolsters our confidence in the stock. However, CMS’ recently proposed Home Health rule in 2017 proved grossly unfavorable for Amedisys indicating gloomy scenario ahead. Also, Escalation in operating expenses and margin contractions continue to raise concern." (5/2/2017)
  • 2. Jefferies Group LLC analysts commented, "We are excited about AMED's 2017 outlook given our view that the company's Q4 performance (margin-driven earnings beat) foreshadows accelerating realization of benefits from its recently-completed IT rollout that should translate into strong earnings power and stock upside. Additionally, AMED's strong balance sheet and robust FCF, coupled with its $100MM EBITDA deal pipeline, should translate to an active year for accretive, upside-driving acquisitions." (3/1/2017)
  • 3. Mizuho analysts commented, "Bumps? What bumps? AMED produced 4Q16 SS home health admit growth, nice margin gains and 15% upside to our adj. EBITDA estimate. For '17E, AMED seems poised to realize $40+mm in actual cost savings, admit growth in HH and continued strong growth in hospice, enough to more than offset a $17 mm hit from HH pricing to achieve EBITDA growth of 28%+ in '17E. But the not-so-cheap stock price "knows" that even though we have no guidance yet and a brand new management team. So we reset our PT at $50 to reflect market re-rating, strong results and the prospect of the real, new AMED emerging in 2017." (3/1/2017)

Who are some of Amedisys' key competitors?

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:

  • Paul B. Kusserow, President, Chief Executive Officer, Director
  • Gary D. Willis, Chief Financial Officer
  • Christopher T. Gerard, Chief Operating Officer
  • Lawrence R. Pernosky, Chief Human Resource Officer
  • Scott G. Ginn, Chief Accounting Officer
  • Michael Paul North, Chief Information Officer
  • David B. Pearce, Chief Compliance Officer
  • David L. Kemmerly, General Counsel
  • Stephen E. Seim, Chief Strategy Officer
  • Susan Sender, Chief Clinical Operations Officer

Who owns Amedisys stock?

Amedisys' stock is owned by a number of of retail and institutional investors. Top institutional investors include Aperio Group LLC (0.07%), Bank of Montreal Can (0.06%), Mitsubishi UFJ Asset Management UK Ltd. (0.06%), Nisa Investment Advisors LLC (0.04%), Louisiana State Employees Retirement System (0.03%) and Sabal Trust CO (0.02%). Company insiders that own Amedisys stock include Bruce D Perkins, Donald A Washburn, Jake L Netterville, Lawrence R Pernosky, North Tide Capital, Llc and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Who sold Amedisys stock? Who is selling Amedisys stock?

Amedisys' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Nisa Investment Advisors LLC and Capstone Asset Management Co.. Company insiders that have sold Amedisys stock in the last year include Jake L Netterville, Lawrence R Pernosky and Scott G Ginn. View Insider Buying and Selling for Amedisys.

Who bought Amedisys stock? Who is buying Amedisys stock?

Amedisys' stock was bought by a variety of institutional investors in the last quarter, including Mitsubishi UFJ Asset Management UK Ltd., Aperio Group LLC and State of Alaska Department of Revenue. View Insider Buying and Selling for Amedisys.

How do I buy Amedisys stock?

Shares of Amedisys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of Amedisys stock can currently be purchased for approximately $59.35.

MarketBeat Community Rating for Amedisys (NASDAQ AMED)
Community Ranking:  1.5 out of 5 ( )
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  299 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amedisys (NASDAQ:AMED) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $58.29 (1.79% downside)

Analysts' Ratings History for Amedisys (NASDAQ:AMED)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/5/2017Royal Bank Of CanadaReiterated RatingHold$56.00LowView Rating Details
5/4/2017StephensBoost Price TargetEqual Weight$50.00 -> $54.00LowView Rating Details
5/3/2017Benchmark Co.Reiterated RatingHold -> Hold$50.00 -> $57.00HighView Rating Details
5/3/2017MizuhoUpgradeNeutral -> Buy$65.00HighView Rating Details
4/28/2017Jefferies Group LLCReiterated RatingBuy$57.00LowView Rating Details
3/3/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$50.00 -> $59.00N/AView Rating Details
1/17/2017Craig HallumSet Price TargetBuy$60.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
5/16/2016Robert W. BairdReiterated RatingHoldN/AView Rating Details
1/11/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformN/AView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$42.00 -> $45.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for Amedisys (NASDAQ:AMED)
Earnings by Quarter for Amedisys (NASDAQ:AMED)
Earnings History by Quarter for Amedisys (NASDAQ AMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017$0.50N/AView Earnings Details
5/2/2017Q1 2017$0.41$0.47$370.03 million$370.46 millionViewListenView Earnings Details
2/28/2017Q4 2016$0.39$0.44$368.14 million$366.30 millionViewN/AView Earnings Details
11/3/2016Q3$0.36$0.36$361.08 million$361.60 millionViewListenView Earnings Details
8/2/2016Q2$0.42$0.42$353.07 million$360.00 millionViewListenView Earnings Details
5/3/2016Q1$0.33$0.33$337.07 million$348.80 millionViewListenView Earnings Details
3/8/2016Q415$0.35$0.40$322.67 million$338.37 millionViewListenView Earnings Details
11/5/2015Q315$0.34$0.34$312.22 million$326.50 millionViewListenView Earnings Details
7/29/2015Q215$0.33$0.43$307.11 million$314.20 millionViewListenView Earnings Details
4/29/2015Q115$0.20$0.30$300.17 million$301.60 millionViewListenView Earnings Details
3/4/2015Q414$0.27$0.27$301.62 million$300.50 millionViewListenView Earnings Details
10/29/2014Q314$0.17$0.28$299.26 million$300.30 millionViewListenView Earnings Details
7/30/2014Q214$0.17$0.25$298.90 million$305.00 millionViewListenView Earnings Details
5/8/2014Q114($0.06)($0.07)$301.89 million$298.74 millionViewListenView Earnings Details
3/12/2014Q413($0.01)($0.05)$295.02 million$303.50 millionViewListenView Earnings Details
11/12/2013Q313$0.13$0.06$314.30 million$301.64 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.10$0.06$328.02 million$313.10 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.18$0.13$361.41 million$339.20 millionViewListenView Earnings Details
3/12/2013Q4 2012$0.22$0.24$373.31 million$632.90 millionViewListenView Earnings Details
11/6/2012Q312$0.27$0.33$379.97 million$375.62 millionViewN/AView Earnings Details
8/7/2012$0.24$0.27ViewN/AView Earnings Details
5/8/2012$0.22$0.22ViewN/AView Earnings Details
2/28/2012$0.29$0.25ViewN/AView Earnings Details
11/1/2011$0.50$0.36ViewN/AView Earnings Details
8/2/2011$0.69$0.75ViewN/AView Earnings Details
4/26/2011$0.66$0.53ViewN/AView Earnings Details
2/22/2011$0.91$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amedisys (NASDAQ:AMED)
2017 EPS Consensus Estimate: $2.02
2018 EPS Consensus Estimate: $2.48
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.40$0.42$0.41
Q2 20173$0.48$0.55$0.51
Q3 20173$0.52$0.53$0.53
Q4 20173$0.57$0.60$0.58
Q1 20182$0.52$0.57$0.55
Q2 20182$0.60$0.61$0.61
Q3 20182$0.64$0.65$0.65
Q4 20182$0.67$0.70$0.69
(Data provided by Zacks Investment Research)


Dividend History for Amedisys (NASDAQ:AMED)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Amedisys (NASDAQ:AMED)
Insider Ownership Percentage: 2.80%
Institutional Ownership Percentage: 99.10%
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017Bruce D PerkinsDirectorBuy500$59.69$29,845.00View SEC Filing  
5/12/2017Jake L NettervilleDirectorSell10,000$60.00$600,000.00View SEC Filing  
5/10/2017Lawrence R PernoskyInsiderSell11,500$58.97$678,155.00View SEC Filing  
5/9/2017Lawrence R PernoskyInsiderSell11,500$58.78$675,970.00View SEC Filing  
5/8/2017Scott G GinnInsiderSell23,828$58.62$1,396,797.36View SEC Filing  
5/13/2016Bruce D PerkinsDirectorBuy1,000$50.21$50,210.00View SEC Filing  
5/11/2016Scott G GinnInsiderSell6,000$51.62$309,720.00View SEC Filing  
11/2/2015North Tide Capital, LlcMajor ShareholderSell277,720$39.79$11,050,478.80View SEC Filing  
10/28/2015North Tide Capital, LlcMajor ShareholderSell191,400$39.86$7,629,204.00View SEC Filing  
10/26/2015North Tide Capital, LlcMajor ShareholderSell56,400$39.32$2,217,648.00View SEC Filing  
8/18/2015Donald A WashburnDirectorSell20,000$45.51$910,200.00View SEC Filing  
3/13/2015Jeffrey D JeterInsiderSell11,264$27.02$304,353.28View SEC Filing  
3/13/2015Peter RicchiutiDirectorSell2,003$27.25$54,581.75View SEC Filing  
8/5/2014Jeffrey D JeterInsiderSell2,500$21.80$54,500.00View SEC Filing  
5/8/2014North Tide Capital, Llcmajor shareholderBuy500,000$13.90$6,950,000.00View SEC Filing  
5/1/2014North Tide Capital, Llcmajor shareholderBuy150,000$13.54$2,031,000.00View SEC Filing  
11/21/2013Kkr Asset Management Llcmajor shareholderBuy425,515$14.48$6,161,457.20View SEC Filing  
11/15/2013David BuceyGeneral CounselSell8,290$13.95$115,645.50View SEC Filing  
11/14/2013Kkr Asset Management Llcmajor shareholderBuy946,500$13.89$13,146,885.00View SEC Filing  
10/30/2013Kkr Asset Management LlcMajor ShareholderBuy29,615$15.94$472,063.10View SEC Filing  
10/22/2013Kkr Asset Management LlcMajor ShareholderBuy186,013$17.55$3,264,528.15View SEC Filing  
10/18/2013Kkr Asset Management LlcMajor ShareholderBuy12,652$17.95$227,103.40View SEC Filing  
7/3/2013Linda J HallDirectorSell1,721$10.65$18,328.65View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amedisys (NASDAQ:AMED)
Latest Headlines for Amedisys (NASDAQ:AMED)
DateHeadline logoAmedisys Inc (NASDAQ:AMED) Receives Consensus Recommendation of "Buy" from Analysts - July 18 at 1:46 PM logoAdCare Health Systems (ADK) & Amedisys (AMED) Financial Analysis - July 17 at 2:31 PM logoETFs with exposure to Amedisys, Inc. : July 14, 2017 - July 14 at 5:36 PM logoAmedisys, Inc. – Value Analysis (NASDAQ:AMED) : July 10, 2017 - July 10 at 3:45 PM logoAmedisys, Inc. breached its 50 day moving average in a Bearish Manner : AMED-US : July 7, 2017 - July 8 at 5:16 AM logoComparing Almost Family (AFAM) & Amedisys (AMED) - July 5 at 10:20 AM logoETFs with exposure to Amedisys, Inc. : July 3, 2017 - July 3 at 3:42 PM logo$380.38 Million in Sales Expected for Amedisys Inc (AMED) This Quarter - June 30 at 12:44 PM logoAmedisys Inc (AMED) Expected to Announce Earnings of $0.50 Per Share - June 28 at 10:06 PM logoAmedisys Inc (AMED) Receives Consensus Rating of "Buy" from Analysts - June 23 at 9:02 AM logoAmedisys Wins Five National Marketing Awards - June 21 at 4:19 PM logoAmedisys settles class action suit, pays $43.75M - June 16 at 4:12 PM logoBRIEF-Amedisys Inc reaches an agreement-in-principle to settle a putative securities class action lawsuit - June 16 at 4:12 PM logoQ1 2018 Earnings Estimate for Amedisys Inc Issued By Oppenheimer Holdings (AMED) - June 12 at 8:12 AM logoETFs with exposure to Amedisys, Inc. : June 8, 2017 - June 8 at 4:12 PM logoAmedisys, Inc. :AMED-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017 - June 6 at 10:47 AM logoAmedisys (AMED) Prospects Impressive Amid Tough Competition - June 6 at 10:47 AM logoAmedisys Inc (AMED) Earns "Hold" Rating from Royal Bank of Canada - June 5 at 9:22 PM logoReviewing LHC Group (LHCG) and Amedisys (AMED) - June 5 at 7:44 AM logoZacks: Analysts Anticipate Amedisys Inc (AMED) Will Announce Quarterly Sales of $380.38 Million - June 4 at 7:52 AM logoAmedisys Inc (AMED) Expected to Post Earnings of $0.50 Per Share - June 2 at 8:32 PM logoWhy Is Amedisys (AMED) Up 4% Since the Last Earnings Report? - June 2 at 4:41 PM logoPaul Kusserow Joins Matrix Medical Network's Board of Directors - May 30 at 11:43 AM logoAmedisys Inc (AMED) Given Consensus Recommendation of "Buy" by Brokerages - May 29 at 9:16 AM logoAmedisys Inc (AMED) Director Purchases $29,845.00 in Stock - May 26 at 1:50 PM logoCMS Rating for Amedisys Home Health Centers Climbs to Average of 4.03 Stars - May 25 at 3:57 PM logoInsider Selling: Amedisys Inc (AMED) Director Sells 10,000 Shares of Stock - May 15 at 7:31 PM logo Brokerages Expect Amedisys Inc (AMED) Will Announce Quarterly Sales of $380.38 Million - May 11 at 11:38 AM logoForm 4 AMEDISYS INC For: May 08 Filed by: Pernosky Lawrence R - May 11 at 1:43 AM logoAmedisys Inc (AMED) Insider Lawrence R. Pernosky Sells 11,500 Shares - May 10 at 11:02 PM logoAmedisys Inc (AMED) Insider Sells $678,155.00 in Stock - May 10 at 11:02 PM logoAmedisys Inc (AMED) Insider Scott G. Ginn Sells 23,828 Shares - May 10 at 1:28 PM logoAmedisys to Present at May and June Healthcare Conferences - May 9 at 1:23 PM logo$0.50 Earnings Per Share Expected for Amedisys Inc (AMED) This Quarter - May 9 at 10:07 AM logoOppenheimer Holdings Analysts Lower Earnings Estimates for Amedisys Inc (AMED) - May 5 at 11:46 AM logoAmedisys Inc to Post Q3 2017 Earnings of $0.53 Per Share, SunTrust Banks Forecasts (AMED) - May 5 at 11:46 AM logoAmedisys Inc (AMED) Rating Reiterated by Stephens - May 4 at 6:18 PM logoJefferies Group Weighs in on Amedisys Inc's Q2 2017 Earnings (AMED) - May 4 at 9:37 AM logoEdited Transcript of AMED earnings conference call or presentation 3-May-17 3:00pm GMT - May 4 at 1:34 AM logoAmedisys (AMED) Getting Favorable News Coverage, Analysis Finds - May 3 at 7:18 PM logoAmedisys Inc (AMED) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS - May 3 at 12:18 PM logoAmedisys Reports First Quarter 2017 Financial Results - May 3 at 8:54 AM logoAmedisys Unveils New Logo, Signifying Its Transformation - May 3 at 8:54 AM logoAmedisys (AMED) Beats on Q1 Earnings, Revenues Meet Mark - May 3 at 8:54 AM logoAmedisys tops Street 1Q forecasts - May 2 at 6:57 PM logoAmedisys Inc (AMED) Receives Consensus Rating of "Hold" from Analysts - May 2 at 10:00 AM logoVery Positive Media Coverage Extremely Likely to Impact Amedisys (AMED) Stock Price - April 30 at 10:10 AM logoAmedisys Inc (AMED) Scheduled to Post Earnings on Tuesday - April 30 at 7:08 AM logoJefferies Group LLC Analysts Give Amedisys Inc (AMED) a $57.00 Price Target - April 29 at 12:11 PM logoFavorable Press Coverage Likely to Impact Amedisys (AMED) Stock Price - April 27 at 2:36 PM



Amedisys (AMED) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff